1. Home
  2. ADMA vs LIVN Comparison

ADMA vs LIVN Comparison

Compare ADMA & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADMA
  • LIVN
  • Stock Information
  • Founded
  • ADMA 2004
  • LIVN 1987
  • Country
  • ADMA United States
  • LIVN United Kingdom
  • Employees
  • ADMA N/A
  • LIVN N/A
  • Industry
  • ADMA Biotechnology: Biological Products (No Diagnostic Substances)
  • LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ADMA Health Care
  • LIVN Health Care
  • Exchange
  • ADMA Nasdaq
  • LIVN Nasdaq
  • Market Cap
  • ADMA 3.5B
  • LIVN 2.9B
  • IPO Year
  • ADMA N/A
  • LIVN 1993
  • Fundamental
  • Price
  • ADMA $16.18
  • LIVN $55.47
  • Analyst Decision
  • ADMA Strong Buy
  • LIVN Strong Buy
  • Analyst Count
  • ADMA 3
  • LIVN 7
  • Target Price
  • ADMA $27.67
  • LIVN $60.00
  • AVG Volume (30 Days)
  • ADMA 3.7M
  • LIVN 527.0K
  • Earning Date
  • ADMA 11-05-2025
  • LIVN 11-05-2025
  • Dividend Yield
  • ADMA N/A
  • LIVN N/A
  • EPS Growth
  • ADMA 205.35
  • LIVN N/A
  • EPS
  • ADMA 0.86
  • LIVN N/A
  • Revenue
  • ADMA $488,559,000.00
  • LIVN $1,348,962,000.00
  • Revenue This Year
  • ADMA $21.08
  • LIVN $10.10
  • Revenue Next Year
  • ADMA $25.98
  • LIVN $7.90
  • P/E Ratio
  • ADMA $18.73
  • LIVN N/A
  • Revenue Growth
  • ADMA 27.63
  • LIVN 8.63
  • 52 Week Low
  • ADMA $13.50
  • LIVN $32.48
  • 52 Week High
  • ADMA $25.67
  • LIVN $58.91
  • Technical
  • Relative Strength Index (RSI)
  • ADMA 58.69
  • LIVN 60.73
  • Support Level
  • ADMA $13.76
  • LIVN $48.82
  • Resistance Level
  • ADMA $15.65
  • LIVN $51.97
  • Average True Range (ATR)
  • ADMA 0.78
  • LIVN 1.78
  • MACD
  • ADMA 0.12
  • LIVN 0.10
  • Stochastic Oscillator
  • ADMA 93.92
  • LIVN 90.48

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

About LIVN LivaNova PLC

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Share on Social Networks: